Replimune Group Inc

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA.

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Replimune (NASDAQ: REPL ) stock is falling hard on Tuesday after the clinical-stage biotechnology company shared a primary analysis of its CERPASS trial. This trial is evaluating RP1 alongside cemiplimab in the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma.

Why Is Replimune (REPL) Stock Down 48% Today?

Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in skin cancer. The therapy, RP1, was studied in combination with cemiplimab, a Regeneron Pharmaceuticals Inc. REGN, +1.04% monoclonal antibody branded as Libtayo.

Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap

Newamsterdam Pharma Co NV

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complex Company backed by leading venture firms, BioGeneration Ventures (BGV) and Forbion World-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in seed funding backed by two leading European venture capital firms, BioGeneration Ventures (BGV) and Forbion. Its lead program targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).

Tessellate BIO Emerges from Stealth

Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. The cutaneous squamous cell carcinoma treatment market is expected to reach $16.86 billion by 2027. Potential to tap into neoadjuvant cutaneous squamous cell carcinoma setting with RP1 by combining it with Incyte's oral PD-L1 inhibitor INCB99280.

Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company's upcoming annual general meeting.

Replimune Announces Sander Slootweg will Depart from its Board of Directors

The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from the CERPASS clinical trial for RP1 combined with Libtayo for cutaneous squamous cell carcinoma are expected in Q3 2023. The partnership with Roche for RP2 and RP3 studies in challenging patient cohorts further emphasizes Replimune's resilience in positioning its treatments as leaders in the biotechnology sector.

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment

Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% (all complete responses) in evaluable patients, with all responses ongoing to date Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% (all complete responses) in evaluable patients, with all responses ongoing to date

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023.

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression in responding patients since the data snapshot presented in December 2022

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.

Replimune to Present at the Jefferies Global Healthcare Conference

WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023.

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track for Q1 2024

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Replimune (REPL) This Earnings Season?

Dualyx r aises € 40 m illion to progress Treg therapies for autoimmune diseases into the clinic

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

The heavy selling pressure might have exhausted for Replimune Group, Inc. (REPL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaround

Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable

Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

The consensus price target hints at an 87.9% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Replimune Group Inc Stock (REPL)